OTC Supplemental Warning Regs Need Not Show Causation – FDA’s Troy
This article was originally published in The Tan Sheet
Executive Summary
FDA does not have to prove causality in order to require new warnings in the labeling of OTC drugs, Chief Counsel Daniel Troy clarified at the Generic Pharmaceutical Association's legal symposium in Washington, D.C. May 16